Public Sector

Drug Pricing Model

The Reden & Anders Drug Pricing Model provides users with the ultimate tool for evaluating the impact on net prescription drug expense. This model develops per-member-per-month (pmpm) expense estimates on both a gross and net basis by re-adjudicating actual claims.

Evaluate prescription drug benefit designs.


A powerful, easy-to-use modeling tool

Use the Reden & Anders Drug Pricing Model to easily quantify the bottom line impact of changes in co-payments and other cost sharing provisions, average wholesale price (AWP) discounts, dispensing fees, claim processing fees and formularies.

Evaluate the affect on your bottom line for:

• The benefit design of the prescription drug plan
• The terms of the underlying pharmacy benefit manager agreement
• Prescription drug formularies
• The underlying demographic mix (age, gender, average contract size, etc.) of the covered population

Tailored outputs

The user can define the desired cost sharing arrangements (co-payments, deductibles, coinsurance, annual maximums), pricing arrangements (AWP discounts and dispensing fees), and membership by age and gender. The output provides pmpm breakdowns between brand/generic and formulary/non-formulary prescriptions to help the payer evaluate where the cost of their prescription drug plan lies.

A competitive advantage in a changing marketplace

The Reden & Anders Drug Pricing Model gives you a distinct advantage in the changing marketplace. The underlying utilization data is updated annually and projected to the desired experience period based on the most recent trend information available.